![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
... rel="self" type="application/rss+xml" />
^
line 53, column 0: (4 occurrences) [help]
<content:encoded><![CDATA[<p><iframe title="YouTube video player" src="h ...
<div style="width: 70px; " class="wp-video"><!--[if lt IE 9]><script>documen ...
<video class="wp-video-shortcode" id="video-11577-1" width="70" height="70" ...
<video class="wp-video-shortcode" id="video-11577-1" width="70" height="70" ...
line 119, column 0: (9 occurrences) [help]
<p><a href="http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807 ...
line 430, column 0: (2 occurrences) [help]
<p>Website: <a href="https://data.pharmacodiaglobal.com/" data-saferedirectu ...
line 577, column 0: (3 occurrences) [help]
<div class="pv-contact-info__ci-container t-14"><span class="style-scope yt- ...
<p>I’m happy to share that I’m starting a new position as Consultant Glenmar ...
<p>I’m happy to share that I’m starting a new position as Consultant Glenmar ...
<p>I’m happy to share that I’m starting a new position as Consultant Glenmar ...
<p>I’m happy to share that I’m starting a new position as Consultant Glenmar ...
line 642, column 0: (25 occurrences) [help]
<div class="r21Kzd" data-hveid="CCoQAQ" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGH ...
line 642, column 0: (16 occurrences) [help]
<div class="r21Kzd" data-hveid="CCoQAQ" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGH ...
line 648, column 0: (5 occurrences) [help]
<div class="wDYxhc" data-md="61">
line 649, column 0: (14 occurrences) [help]
<div class="LGOjhe" data-attrid="wa:/description" data-hveid="CB8QAA"><span ...
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" > <channel> <title>All About Drugs</title> <atom:link href="https://www.allfordrugs.com/feed/" rel="self" type="application/rss+xml" /> <link>https://www.allfordrugs.com</link> <description> Tout sur les médicaments הכל על תרופות كل شيئ عن الأدوية Все о наркотиках 关于药品的一切 డ్రగ్స్ గురించి అన్ని 마약에 관한 모든 것 Όλα για τα Ναρκωτικά Complete Tracking of Drugs Across the World by Dr Anthony Melvin Crasto, Worldpeacepeaker, worlddrugtracker, PH.D (ICT), MUMBAI, INDIA, Worlddrugtracker, Helping millions, 9 million hits on google on all websites, 2.5 lakh connections on all networks, “ALL FOR DRUGS” CATERS TO EDUCATION GLOBALLY, No commercial exploits are done or advertisements added by me. This is a compilation for educational purposes only. P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent</description> <lastBuildDate>Mon, 16 Sep 2024 13:21:24 +0000</lastBuildDate> <language>en-US</language> <sy:updatePeriod>hourly</sy:updatePeriod> <sy:updateFrequency>1</sy:updateFrequency> <generator>https://wordpress.org/?v=4.4.33</generator> <item> <title>Zamaporvint</title> <link>https://www.allfordrugs.com/2024/09/16/zamaporvint/</link> <pubDate>Mon, 16 Sep 2024 13:21:24 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[Uncategorized]]></category> <category><![CDATA[phase 2]]></category> <category><![CDATA[RX C004]]></category> <category><![CDATA[RXC004]]></category> <category><![CDATA[Zamaporvint]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11606</guid> <description><![CDATA[Zamaporvint   READ ALL AT https://newdrugapprovals.org/2024/09/15/zamaporvint/]]></description> <content:encoded><![CDATA[<h1 class="title-header">Zamaporvint</h1><p> </p><p>READ ALL AT</p><p><a href="https://newdrugapprovals.org/2024/09/15/zamaporvint/">https://newdrugapprovals.org/2024/09/15/zamaporvint/</a></p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2024%2F09%2F16%2Fzamaporvint%2F&title=Zamaporvint" id="wpa2a_2"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>Smartchem by Row2 Technologies</title> <link>https://www.allfordrugs.com/2023/03/09/smartchem-by-row2-technologies/</link> <pubDate>Thu, 09 Mar 2023 13:32:58 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[spotlight]]></category> <category><![CDATA[ANAND]]></category> <category><![CDATA[anthony crasto]]></category> <category><![CDATA[Row2 Technologies]]></category> <category><![CDATA[Smartchem]]></category> <category><![CDATA[WORLD DRUG TRACKER]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11577</guid> <description><![CDATA[Are you aware of any Chemical Database which offers one stop solution to the Sourcing, R&D and Business Development department? Explore Smartchem to Quickly find Suppliers (Procurement), Customers (BD) & Synthetic pathways (R&D) Is this the information you looking for? Evaluate SmartChem, lets schedule a demo. Try us once. You will use us for life. <a href='https://www.allfordrugs.com/2023/03/09/smartchem-by-row2-technologies/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><iframe title="YouTube video player" src="https://www.youtube.com/embed/igiau1OvzYM" width="560" height="315" frameborder="0" allowfullscreen="allowfullscreen"></iframe><br />Are you aware of any Chemical Database which offers one stop solution to the Sourcing, R&D and Business Development department? Explore Smartchem to Quickly find Suppliers (Procurement), Customers (BD) & Synthetic pathways (R&D)</p><p>Is this the information you looking for? Evaluate SmartChem, lets schedule a demo. Try us once. You will use us for life.</p><p>Anand Ramakrishnan |Vice President – Sales & Operations | +91 9821384045 | +1 973-795-1141 | ranand@row2technologies.com | www.row2technologies.com | WhatsApp: +91 9821384045</p><p>Anthony Crasto | Advisor | +91 9321316780 | c_acrasto@row2technologies.com | amcrasto@gmail.com | www.row2technologies.com | WhatsApp: +91 9321316780 |</p><p> </p><div style="width: 70px; " class="wp-video"><!--[if lt IE 9]><script>document.createElement('video');</script><![endif]--><video class="wp-video-shortcode" id="video-11577-1" width="70" height="70" preload="metadata" controls="controls"><source type="video/mp4" src="http://www.allfordrugs.com/wp-content/uploads/2023/03/row2-1-video.mp4?_=1" /><a href="http://www.allfordrugs.com/wp-content/uploads/2023/03/row2-1-video.mp4">http://www.allfordrugs.com/wp-content/uploads/2023/03/row2-1-video.mp4</a></video></div><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2023%2F03%2F09%2Fsmartchem-by-row2-technologies%2F&title=Smartchem%20by%20Row2%20Technologies" id="wpa2a_4"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> <enclosure url="http://www.allfordrugs.com/wp-content/uploads/2023/03/row2-1-video.mp4" length="0" type="video/mp4" /> </item> <item> <title>Myself Anthony Crasto up for grabs as Advisor API & INT, Chem.</title> <link>https://www.allfordrugs.com/2023/01/23/myself-anthony-crasto-up-for-grabs-as-advisor-api-int-chem/</link> <pubDate>Mon, 23 Jan 2023 06:09:06 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[ANTHONY CRASTO]]></category> <category><![CDATA[blogs]]></category> <category><![CDATA[ADVISOR]]></category> <category><![CDATA[anthony crasto]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11572</guid> <description><![CDATA[Admin note for myself . I am up for Grabs I myself Dr Anthony Melvin Crasto Looking for a post retirement assignment as Advisor API & INT, Chem. With 36 yrs rich experience, about dozen patents, 10000plus steps covered, 200 API targets, 30 plus products commercialization in plant in full career. Hands on knowledge of <a href='https://www.allfordrugs.com/2023/01/23/myself-anthony-crasto-up-for-grabs-as-advisor-api-int-chem/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><!-- wp:paragraph --></p><p>Admin note for myself . I am up for Grabs</p><p><!-- /wp:paragraph --> <!-- wp:paragraph --></p><p>I myself Dr Anthony Melvin Crasto Looking for a post retirement assignment as Advisor API & INT, Chem.<br />With 36 yrs rich experience, about dozen patents, 10000plus steps covered, 200 API targets, 30 plus products commercialization in plant in full career. Hands on knowledge of Synthesis, Process, scaleup, cost reduction, DOE , softwares etc</p><p><!-- /wp:paragraph --> <!-- wp:paragraph --></p><p>Kindly contact me<br />Dr Anthony Melvin Crasto<br />+919321316780<br /><a href="mailto:amcrasto@gmail.com">amcrasto@gmail.com</a></p><p><!-- /wp:paragraph --> <!-- wp:paragraph --></p><p>About myself<br />Dr Anthony Crasto<br />click on my website to know about me</p><p><!-- /wp:paragraph --> <!-- wp:paragraph --></p><p>Read <a href="http://amcrasto.weebly.com/" target="_blank">http://amcrasto.weebly.com/</a><br />Also <a href="http://amcrasto.weebly.com/awards.html" target="_blank">http://amcrasto.weebly.com/awards.html</a><br />Also<br /><a href="http://amcrasto.weebly.com/felicitations.html" target="_blank">http://amcrasto.weebly.com/felicitations.html</a></p><p><!-- /wp:paragraph --> <!-- wp:paragraph --></p><p>1000 lakh google hits, 100lakh blog views, 10 lakh viewers in USA alone, all in 7 continents, 226 countries, 30 Indian and International awards, helping millions across the world</p><p><!-- /wp:paragraph --> <!-- wp:image {"id":26263,"sizeSlug":"large","linkDestination":"media"} --></p><figure class="wp-block-image size-large"><a href="https://newdrugapprovals.files.wordpress.com/2023/01/cons-open-a-m-crasto.jpg"><img class="wp-image-26263" src="https://newdrugapprovals.files.wordpress.com/2023/01/cons-open-a-m-crasto.jpg?w=1024" alt="" /></a></figure><p><!-- /wp:image --></p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2023%2F01%2F23%2Fmyself-anthony-crasto-up-for-grabs-as-advisor-api-int-chem%2F&title=Myself%20Anthony%20Crasto%20up%20for%20grabs%20as%20Advisor%20API%20%26%20INT%2C%20Chem." id="wpa2a_6"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. ANTHONY CRASTO</title> <link>https://www.allfordrugs.com/2023/01/17/top-10-prominent-great-personalities-of-the-year-2022-campaign-by-fame-finders-anthony-crasto/</link> <pubDate>Tue, 17 Jan 2023 03:23:56 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[ANTHONY CRASTO]]></category> <category><![CDATA[award]]></category> <category><![CDATA[blogs]]></category> <category><![CDATA[anthony crasto]]></category> <category><![CDATA[TOP10]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11560</guid> <description><![CDATA[‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. Feeling great to be selected in the ‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. It is an online campaign to honour inspiring personalities and feature them in the upcoming edition of the top news <a href='https://www.allfordrugs.com/2023/01/17/top-10-prominent-great-personalities-of-the-year-2022-campaign-by-fame-finders-anthony-crasto/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><iframe title="YouTube video player" src="https://www.youtube.com/embed/x98E01m9anw" width="560" height="315" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p><p>‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders.<br />Feeling great to be selected in the ‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. It is an online campaign to honour inspiring personalities and feature them in the upcoming edition of the top news sites, including – Deccan Chronicle/Asian Age/Deccan Herald, ANI, Zee5, Latestly, Lokmat Times, DailyHunt, Google News, JioNews, MSN and 70+ sites.Jan 16 2023</p><p>LINK <a href="https://www.deccanherald.com/brandspot/pr-spot/top-10-prominent-and-great-personalities-of-the-year-2022-announced-by-fame-finders-media-1181964.html" target="_blank">https://www.deccanherald.com/brandspot/pr-spot/top-10-prominent-and-great-personalities-of-the-year-2022-announced-by-fame-finders-media-1181964.html</a></p><p><a href="http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807179.jpg" rel="attachment wp-att-11561"><img class="alignnone size-full wp-image-11561" src="http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807179.jpg" alt="1673870807179" width="1280" height="988" srcset="http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807179-300x232.jpg 300w, http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807179-768x593.jpg 768w, http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807179-1024x790.jpg 1024w, http://www.allfordrugs.com/wp-content/uploads/2023/01/1673870807179.jpg 1280w" sizes="(max-width: 1280px) 100vw, 1280px" /></a> <a href="http://www.allfordrugs.com/wp-content/uploads/2023/01/TOP-10.jpg" rel="attachment wp-att-11562"><img class="alignnone size-full wp-image-11562" src="http://www.allfordrugs.com/wp-content/uploads/2023/01/TOP-10.jpg" alt="TOP 10" width="738" height="621" srcset="http://www.allfordrugs.com/wp-content/uploads/2023/01/TOP-10-300x252.jpg 300w, http://www.allfordrugs.com/wp-content/uploads/2023/01/TOP-10.jpg 738w" sizes="(max-width: 738px) 100vw, 738px" /></a></p><p><img src="https://newdrugapprovals.files.wordpress.com/2023/01/deccan-herald-1.jpg?w=1024" alt="" /><img src="https://newdrugapprovals.files.wordpress.com/2023/01/deccan-herald-2.jpg?w=808" alt="" /></p><p> </p><p>PRESS RELEASE COVERAGE REPORT- FAME FINDERS MEDIA<br />Headline – Top 10 Prominent and Dynamic Personalities to watch in 2023<br />SNo Publication Link</p><p>1 ANI https://www.aninews.in/news/business/business/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105508/</p><p>2 Dailyhunt</p><p>https://m.dailyhunt.in/news/india/english/ani67917250816496966-epaper-<br />anieng/top+10+prominent+and+dynamic+personalities+to+watch+in+2023-newsid-<br />n480757892?listname=newspaperLanding&index=22&topicIndex=4&mode=pwa&action=click</p><p>3 Zee5 https://www.zee5.com/articles/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-2023</p><p>4 Latestly</p><p>https://www.latestly.com/agency-news/business-news-top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023-4952899.html</p><p>5 Kolkata News</p><p>https://www.kolkatanews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>6 Kulalimpur News</p><p>https://www.kualalumpurnews.net/news/273634192/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023</p><p>7 Mumbai News</p><p>https://www.mumbainews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>8 Srilanka Source</p><p>https://www.srilankasource.com/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>9 Bignews<br />Network</p><p>https://www.bignewsnetwork.com/news/273634192/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023</p><p>10 Nepal National https://www.nepalnational.com/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>11 South East Asia<br />Post</p><p>https://www.southeastasiapost.com/news/273634192/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023</p><p>12 Bangkok News</p><p>https://www.bangkoknews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>13 Brunei News</p><p>https://www.bruneinews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>14 The Cambodia<br />News</p><p>https://www.thecambodianews.net/news/273634192/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023</p><p>15 New Delhi News</p><p>https://www.newdelhinews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>16 Cambodian<br />times</p><p>https://www.cambodiantimes.com/news/273634192/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023</p><p>17 Bangladesh Sun</p><p>https://www.bangladeshsun.com/news/273634192/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-2023</p><p>18 Laos News</p><p>https://www.laosnews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>19 Nepal News</p><p>https://www.nepalnews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>20 Pakistan News</p><p>https://www.pakistannews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>21 India’s News</p><p>https://www.indiasnews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>22 Malaysian News</p><p>https://www.malaysianews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>23 Indonesian<br />News</p><p>https://www.indonesianews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>24 Sri Lankan News</p><p>https://www.srilankannews.net/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>25 Herald Globe</p><p>https://www.heraldglobe.com/news/273634192/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-2023</p><p>26 West Bengal<br />Khabar</p><p>https://www.WestBengalKhabar.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>27 Vanakkam<br />Tamilnadu</p><p>https://www.VanakkamTamilnadu.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>28 UP Today</p><p>https://www.UPtoday.news/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>29 Telangana<br />Journal</p><p>https://www.Telanganajournal.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>30 South India<br />News</p><p>https://www.SouthIndiaNews.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>31 Punjab Live</p><p>https://www.PunjabLive.news/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>32 Odisha Post</p><p>https://www.OdishaPost.news/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>33 North East Times</p><p>https://www.NorthEastTimes.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>34 Maharashtra<br />Samachar</p><p>https://www.MaharashtraSamachar.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>35 Madhya Pradesh<br />Chronicle</p><p>https://www.MadhyaPradeshChronicle.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>36 Kashmir<br />Newsline</p><p>https://www.KashmirNewsline.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>37 Kashmir<br />Breaking News</p><p>https://www.KashmirBreakingNews.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>38 Karnataka Live</p><p>https://www.KarnatakaLive.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>39 Jharkhand Times</p><p>https://www.JharkhandTimes.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>40 Indian Economic<br />Observer</p><p>https://www.IndianEconomicObserver.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>41 Himachal Patrika</p><p>https://www.HimachalPatrika.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>42 Haryana Today</p><p>https://www.HaryanaToday.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>43 Gujrat Varta</p><p>https://www.GujaratVarta.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>44 Delhi Live News</p><p>https://www.DelhiLiveNews.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>45 Chhattisgarh<br />Today</p><p>https://www.ChhattisgarhToday.in/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>46 Bihar Times</p><p>https://www.BiharTimes.news/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>47 Bihar 24×7 https://www.Bihar24x7.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>48 Andhra Pradesh https://www.AndhraPradeshMirror.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>49 World News<br />Network</p><p>https://www.worldnewsnetwork.net/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>50 Birmingham All<br />News Network</p><p>https://www.birminghamallnewsnetwork.com/news/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-202320230316105500/</p><p>51 British Columbia<br />Times</p><p>https://www.britishcolumbiatimes.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>52 British News<br />Network</p><p>https://www.britishnewsnetwork.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>53 Buffalo Despatch https://www.buffalodespatch.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>54 Capitol Hill<br />Reporter</p><p>https://www.capitolhillreporter.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>55 Dubai City<br />Reporter</p><p>https://www.dubaicityreporter.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>56 East Asia All<br />News Portal</p><p>https://www.eastasiaallnewsportal.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>57 East Coast<br />America News</p><p>https://www.eastcoastamericannews.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>58 England News<br />Portal</p><p>https://www.englandnewsportal.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>59 Eauropean Sun<br />Times</p><p>https://www.europeansuntimes.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>60 Federal<br />Despatch</p><p>https://www.federaldespatch.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>61 Florida Breaking<br />News</p><p>https://www.floridabreakingnews.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>62 France Network<br />Times</p><p>https://www.francenetworktimes.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>63 London Channel<br />News</p><p>https://www.londonchannelnews.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>64</p><p>Los Angeles<br />Evening<br />Despatch</p><p>https://www.losangeleseveningdespatch.com/news/top-10-prominent-<br />and-dynamic-personalities-to-watch-in-202320230316105500/</p><p>65 Maldives Star<br />Plus</p><p>https://www.maldivesstarplus.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>66 Miami News<br />Herald</p><p>https://www.miaminewsherald.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>67 Mountain View<br />Sentinel</p><p>https://www.mountainviewsentinel.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>68 NewYork<br />Despatch</p><p>https://www.newyorkdespatch.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>69 Richmond<br />Evening News</p><p>https://www.richmondeveningnews.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>70 Sri Lanka Island<br />News</p><p>https://www.srilankaislandnews.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>71 Toronto Sun<br />Times</p><p>https://www.torontosuntimes.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>72 US World Today</p><p>https://www.usworldtoday.com/news/top-10-prominent-and-dynamic-<br />personalities-to-watch-in-202320230316105500/</p><p>73 Washington Dc<br />Despatch</p><p>https://www.washingtondcdespatch.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>74 WhiteHouse<br />News Time</p><p>https://www.whitehousenewstime.com/news/top-10-prominent-and-<br />dynamic-personalities-to-watch-in-202320230316105500/</p><p>///////</p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2023%2F01%2F17%2Ftop-10-prominent-great-personalities-of-the-year-2022-campaign-by-fame-finders-anthony-crasto%2F&title=%E2%80%98Top%2010%20Prominent%20%26%20Great%20Personalities%20of%20the%20year%202022%E2%80%99%20campaign%20by%20Fame%20Finders.%20ANTHONY%20CRASTO" id="wpa2a_8"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>Dr. D Srinivasa Reddy appointed Director CSIR-IICT Hyderabad on 7th June 2022. A new assignment</title> <link>https://www.allfordrugs.com/2022/06/08/dr-d-srinivasa-reddy-appointed-director-csir-iict-hyderabad-on-7th-june-2022-a-new-assignment/</link> <pubDate>Wed, 08 Jun 2022 02:12:11 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[Uncategorized]]></category> <category><![CDATA[CSIR-IICT]]></category> <category><![CDATA[Director]]></category> <category><![CDATA[Hyderabad]]></category> <category><![CDATA[India.]]></category> <category><![CDATA[srinivasa reddy]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11521</guid> <description><![CDATA[Dr. D Srinivasa Reddy appointed Director CSIR-IICT Hyderabad India on 7th June 2022. A new assignment This is on recommendation from search cum selection committee which met Prime minister who is president CSIR on 2nd may 2022 currently he is Director CSIR-IIIM jammu we wish him all the best in New assignment D. Srinivasa Reddy <a href='https://www.allfordrugs.com/2022/06/08/dr-d-srinivasa-reddy-appointed-director-csir-iict-hyderabad-on-7th-june-2022-a-new-assignment/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><img src="http://www.allfordrugs.com/wp-content/uploads/2022/06/STR2.jpg" alt="STR2" /></p><div class="kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x c1et5uql ii04i59q"><div dir="auto"><a href="http://www.allfordrugs.com/wp-content/uploads/2022/06/str1.jpg" rel="attachment wp-att-11522"><img class="alignnone size-full wp-image-11522" src="http://www.allfordrugs.com/wp-content/uploads/2022/06/str1.jpg" alt="str1" width="608" height="960" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/06/str1-190x300.jpg 190w, http://www.allfordrugs.com/wp-content/uploads/2022/06/str1.jpg 608w" sizes="(max-width: 608px) 100vw, 608px" /></a></div></div><div dir="auto"><p><!-- wp:paragraph -->Dr. D Srinivasa Reddy appointed Director CSIR-IICT Hyderabad India on 7th June 2022. A new assignment</p><p><!-- /wp:paragraph --> <!-- wp:paragraph -->This is on recommendation from search cum selection committee which met Prime minister who is president CSIR on 2nd may 2022</p><p><!-- /wp:paragraph --> <!-- wp:paragraph -->currently he is Director CSIR-IIIM jammu</p><p><!-- /wp:paragraph --> <!-- wp:paragraph -->we wish him all the best in New assignment</p><p><!-- /wp:paragraph --> <!-- wp:paragraph -->D. Srinivasa Reddy (DSReddy)</p><p><!-- /wp:paragraph --></p></div><div dir="auto">………….Srinivasa Reddy, Director, CSIR-IICT, Hyderabad, india</div><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2022%2F06%2F08%2Fdr-d-srinivasa-reddy-appointed-director-csir-iict-hyderabad-on-7th-june-2022-a-new-assignment%2F&title=Dr.%20D%20Srinivasa%20Reddy%20appointed%20Director%20CSIR-IICT%20Hyderabad%20on%207th%20June%202022.%20A%20new%20assignment" id="wpa2a_10"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>Pharmacodia Intelligence/”Internet+” big data information platform for pharmaceutical R&D</title> <link>https://www.allfordrugs.com/2022/04/12/pharmacodia-intelligenceinternet-big-data-information-platform-for-pharmaceutical-rd/</link> <pubDate>Tue, 12 Apr 2022 09:01:05 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[Uncategorized]]></category> <category><![CDATA[pharmacodia]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11509</guid> <description><![CDATA[  How are you? Please allow me to introduce Pharmacodia global drug Database & services to you briefly. Pharmacodia Global Pharmaceutical Intelligence Platform is the first tier drug database for R&D Professionals including 40,000+ Drug data, 13,817,000+ Patents, 488,000+ Registration & Approval, 414,000+ Clinical Trials and 63,000+ items related regulatory policies. Focusing on the drug <a href='https://www.allfordrugs.com/2022/04/12/pharmacodia-intelligenceinternet-big-data-information-platform-for-pharmaceutical-rd/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><a href="http://www.allfordrugs.com/wp-content/uploads/2022/04/str2.jpg" rel="attachment wp-att-11512"><img class="alignnone size-full wp-image-11512" src="http://www.allfordrugs.com/wp-content/uploads/2022/04/str2.jpg" alt="str2" width="1000" height="316" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/04/str2-300x95.jpg 300w, http://www.allfordrugs.com/wp-content/uploads/2022/04/str2-768x243.jpg 768w, http://www.allfordrugs.com/wp-content/uploads/2022/04/str2.jpg 1000w" sizes="(max-width: 1000px) 100vw, 1000px" /></a></p><p> </p><p>How are you? Please allow me to introduce Pharmacodia global drug Database & services to you briefly.<br />Pharmacodia Global Pharmaceutical Intelligence Platform is the first tier drug database for R&D Professionals including 40,000+ Drug data, 13,817,000+ Patents, 488,000+ Registration & Approval, 414,000+ Clinical Trials and 63,000+ items related regulatory policies.</p><p>Focusing on the drug research and development, Pharmacodia global database includes all small molecule drugs and biologics since 1982 (either in developing or marketed in the world). You may have a three days free trial for the Database.</p><p>Website: <a href="https://data.pharmacodiaglobal.com/" data-saferedirecturl="https://www.google.com/url?q=https://data.pharmacodiaglobal.com&source=gmail&ust=1649839348684000&usg=AOvVaw22aNqyeW7GyjtvSQvvnNfw"><strong>https://data.pharmacodiaglobal.com</strong></a><br />If your colleagues and friends like to have a trial for the database, would you please forward the email to them, they can easily register an account and apply for a one day free trail. Thank you very much.</p><p> </p><p><iframe src="https://onedrive.live.com/embed?cid=FC3071A5D7797DD2&resid=FC3071A5D7797DD2%21698&authkey=AEyGmKgcCfylBYQ&em=2" width="647" height="647" frameborder="0" scrolling="no"></iframe></p><p><img class="" src="https://i0.wp.com/codemyui.com/wp-content/uploads/2016/10/gooey-scroll-arrow.gif?fit=690%2C345&ssl=1" alt="67 Scroll Animation Design Inspiration - HTML & CSS Snippets Ξ Page 5 Of 8 Ξ ℂ𝕠𝕕𝕖𝕄𝕪𝕌𝕀" width="160" height="80" />SCROLL UP OR DOWN</p><p>Sincerely yours,</p><p><img class="" src="http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0025.jpg" alt="IMG-20220412-WA0025" width="222" height="305" /></p><p>Jim<br />Chair of Pharmacodia Group<br />HongKong</p><p><b><span lang="EN-US">If you are interested in knowing more about our database and services, please contact us through email/whatsApp:</span></b></p><p><strong><a href="mailto:global@pharmacodia.com">global@pharmacodia.com</a></strong></p><p><b><span lang="EN-US">WhatsApp Number</span></b></p><table style="font-weight: 400; height: 133px;" width="669"><tbody><tr><td width="188"><strong>Jin: +86 138 1146 5766</strong></td><td width="188"><strong> </strong></p><p><strong>Sheryl: +86 138 1072 1280</strong></td><td width="188"><strong> </strong></p><p><strong>Alex: +44 736 025 310</strong></td></tr></tbody></table><p><a href="http://www.allfordrugs.com/wp-content/uploads/2022/04/str1.jpg" rel="attachment wp-att-11511"><img class="alignnone wp-image-11511" src="http://www.allfordrugs.com/wp-content/uploads/2022/04/str1.jpg" alt="str1" width="659" height="134" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/04/str1-300x61.jpg 300w, http://www.allfordrugs.com/wp-content/uploads/2022/04/str1.jpg 735w" sizes="(max-width: 659px) 100vw, 659px" /></a></p><p><img class="alignnone wp-image-11517" src="http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0026.jpg" alt="IMG-20220412-WA0026" width="318" height="477" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0026-200x300.jpg 200w, http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0026-683x1024.jpg 683w, http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0026.jpg 720w" sizes="(max-width: 318px) 100vw, 318px" /></p><p>SHERYL DING</p><p>CEO</p><p> </p><p><img class="alignnone wp-image-11516" src="http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0027.jpg" alt="IMG-20220412-WA0027" width="320" height="480" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0027-200x300.jpg 200w, http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0027-683x1024.jpg 683w, http://www.allfordrugs.com/wp-content/uploads/2022/04/IMG-20220412-WA0027.jpg 720w" sizes="(max-width: 320px) 100vw, 320px" /></p><p>ALEX</p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2022%2F04%2F12%2Fpharmacodia-intelligenceinternet-big-data-information-platform-for-pharmaceutical-rd%2F&title=Pharmacodia%20Intelligence%2F%E2%80%9DInternet%2B%E2%80%9D%20big%20data%20information%20platform%20for%20pharmaceutical%20R%26D" id="wpa2a_12"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>Pharmaceutical eMES (eBMR) – why and how?</title> <link>https://www.allfordrugs.com/2022/02/21/pharmaceutical-emes-ebmr-why-and-how/</link> <pubDate>Mon, 21 Feb 2022 08:14:41 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[Uncategorized]]></category> <category><![CDATA[CEO]]></category> <category><![CDATA[Laurus Infosystems]]></category> <category><![CDATA[PRIYA RANJAN BELWARIAR]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11474</guid> <description><![CDATA[PRIYA RANJAN BELWARIAR CEO, Laurus Infosystems (Guest article) Pharmaceutical eMES (eBMR) – why and how? The “e Manufacturing Execution System” for pharmaceutical manufacturing is different from eMES in any other manufacturing industry. The difference primarily comes from the stringent Regulatory Compliance norms to be adhered to in Pharmaceutical Operations. In the Pharmaceutical Manufacturing the eMES <a href='https://www.allfordrugs.com/2022/02/21/pharmaceutical-emes-ebmr-why-and-how/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><a href="http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-1.jpg" rel="attachment wp-att-11475"><img class="alignnone size-full wp-image-11475" src="http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-1.jpg" alt="str1" width="214" height="239" /></a></p><p>PRIYA RANJAN BELWARIAR</p><p>CEO, Laurus Infosystems</p><p>(Guest article)</p><p><strong>Pharmaceutical eMES (eBMR) – why and how?</strong></p><p>The “e Manufacturing Execution System” for pharmaceutical manufacturing is different from eMES in any other manufacturing industry. The difference primarily comes from the stringent Regulatory Compliance norms to be adhered to in Pharmaceutical Operations. In the Pharmaceutical Manufacturing the eMES is also referred as eBMR or “e Batch Manufacturing Record”.</p><p>The key <strong>objectives</strong> of implementing “e Manufacturing Execution Systems” (or eBMR) in Pharma Manufacturing are:</p><ol><li><strong>Achieve Compliance</strong>with global regulatory norms, quality processes and ALCOA + norms.</li><li><strong>Achieve Data integrity</strong>across functions, systems and equipment records.</li><li><strong>Audit readiness: </strong>Become ever ready for audit, with complete electronic records.</li><li><strong>Paperless operation: </strong>Achieve paperless (or less paper) operation at the plant.</li></ol><p> </p><p>Pharmaceutical companies operate in one of the most dynamic and highly regulated environments. Regulatory audit frequencies have increased. Warning letters & import restrictions incidences have increased alongside. Many companies fail in clearing Regulatory Audits. Failing an audit results in over two years of business loss and huge expenses in achieving success with re-audit.</p><p>Most of the Pharmaceutical Manufacturing organizations have realized that they must implement a comprehensive eMES/eBMR systems for achieving the stated objective for long term business survival in todays regulated environment. However, the existing infrastructure scenario, inhibit moving forward with such implementation.</p><p><strong>The scenario</strong>: Many Pharmaceutical Manufacturing Units are supplying to strongly regulated markets. They have a mix of the following infrastructure scenario:</p><ol><li><strong>Obsolete Equipment</strong>: Some equipment are obsolete in their design. These have no digital ability to record and communicate critical operations parameters for recording into BMR.</li><li><strong>Semi-modern equipment</strong>: Some equipment have some digital ability to show records but are not enabled for automatic data transmission to SCADA database.</li></ol><p><strong>Modern Equipment</strong>: Some equipment are modern, PLC controlled and they can store digital data for some time. They still need to be integrated to SCADA (Supervisory Control And Data Acquisition) system.</p><p>There are also several cases of failures in implementing eMES solution provided by global brands providing the MES solution. Some of the key reasons of eMES implementation project failures are:</p><ol><li><strong>Complexity of the eMES</strong>Software systems. The level of complexity that can be digested across continents vary a lot. What is simple for some European countries may be too complex for Asian countries.</li><li><strong>Design and Architecture of MES Solutions: </strong>A generic MES, modified for Pharma, would not succeed in Pharma. The eMES must be designed for Pharmaceutical operations, where the regulatory compliance requires flexibility in system to allow special process steps, for which there is no global best practices. The system must be architected for allowing new recipe, new product and new process to be quickly configured.</li><li><strong>Right collaboration: </strong>Very often IT Team of Pharma companies would be good at handling the ERP Software and Level 3 & Level 4 IT systems. They would lack expertise of Level 1 and Level 2 Automation. Companies need to get right IT Solution providers capable of supplying and implementation right eMES along with Automation Solutions.</li><li><strong>Comprehensive Solution: </strong>A comprehensive solution design would encompass eMES, integration with ERP, integration with SCADA and direct integration with many devices. The SCADA and Automation solution would include upgrading the semi modern equipment, connecting them along with modern equipment to SCADA. Adopting right strategy solution for obsolete equipment.</li></ol><p><strong>Phased implementation Strategy</strong>: There is variety of strategies for eMES implementation with complete automation integration. Designing and selecting right strategy is a Critical Success Factor.</p><p>The country, the facility location, equipment vendors, employees, organization culture, the product and market combination etc., makes every unit and unique unit. The eMES solution must be designed to suit each such unit. One solution would not fit all. The solutions must be configurable for taking care of the uniqueness. <strong>The solutions must be robust and maintainable</strong>.</p><p> </p><p>Laurel MES™ product suite for “e Manufacturing Execution” is architected and designed for Pharmaceutical Manufacturing businesses to achieve compliance and audit readiness. Laurel MES™ comes along with Automation Solution and Systems Integration Solution which provides a complete, comprehensive and configurable solution. The drug product variants, market variants and product changeover challenges are addressed as required. Management dashboards and scorecards are fascinating. This solution is integration-ready for latest manufacturing and testing equipment.</p><p><strong>Website: </strong><a href="http://www.laurelmes.com/"><strong>www.laurelmes.com</strong></a><strong> . Write to: </strong><a href="http://mailto:pr.belwariar@laurusis.com/"><strong>pr.belwariar@laurusis.com</strong></a></p><table style="height: 378px;" width="631"><tbody><tr><td colspan="2" width="929"><strong>Priya Ranjan Belwariar</strong></td></tr><tr><td colspan="2" width="929">CEO</td></tr><tr><td colspan="2" width="929"></td></tr><tr><td width="507">Laurus Infosystems (India) Pvt. Ltd.</p><p>3<sup>rd</sup> Floor, Plot # 8, 1<sup>st</sup> Cross,</p><p>Sadaramangala Industrial Area <strong>|</strong> Whitefield</p><p>Bangalore – 560 066 <strong>|</strong> India</td><td width="422"><strong>T</strong> +91 80 6152 7801</p><p><strong>M </strong>+91 99 7242 4444</p><p><strong>E </strong><a href="mailto:pr.belwariar@laurusis.com">pr.belwariar@laurusis.com</a></p><p><strong>W </strong><a href="http://laurusis.com/" data-saferedirecturl="https://www.google.com/url?q=http://laurusis.com&source=gmail&ust=1645516802983000&usg=AOvVaw3T2X2OZyebzl3JzqUuB1Do">laurusis.com</a></td></tr><tr><td width="507"></td><td width="422"><strong>Next Generation</strong><strong> </strong><strong>Innovation</strong></td></tr></tbody></table><p> </p><h3 class="pv-contact-info__header t-16 t-black t-bold">Priya Ranjan’s Profile</h3><div class="pv-contact-info__ci-container t-14"><a class="pv-contact-info__contact-link link-without-visited-state t-14" href="https://www.linkedin.com/in/pr-belwariar">linkedin.com/in/pr-belwariar</a></div><p>Experienced Chief Executive Officer with a track record of leading Architecture Design and development of Software Products for Pharma Manufacturing Execution, Pharma R&D and making it successful in the market. Demonstrated strength in the information technology, software technologies, software services, Pharma, Chemical and Engineering industry. Skilled in Business Process, Architecture and Design of Enterprise Software and Computer Integrated Manufacturing. Strong business development professional with Engineering and MBA qualifications.</p><p> </p><p>//////////////</p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2022%2F02%2F21%2Fpharmaceutical-emes-ebmr-why-and-how%2F&title=Pharmaceutical%20eMES%20%28eBMR%29%20%E2%80%93%20why%20and%20how%3F" id="wpa2a_14"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>What is investigational new drug (IND) Application? Neha parashar</title> <link>https://www.allfordrugs.com/2022/02/18/what-is-investigational-new-drug-ind-application-neha-parashar/</link> <pubDate>Fri, 18 Feb 2022 13:52:05 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[Uncategorized]]></category> <category><![CDATA[ind]]></category> <category><![CDATA[neha parashar]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11470</guid> <description><![CDATA[What is Investigational New Drug (IND) Application? | Regulatory Learnings | Drug Regulatory Affairs https://www.youtube.com/watch?v=NTOtI7HfE9I       GUEST AUTHOR Neha Parashar, PMP® Senior Manager Regulatory CMC | Regulatory Project Management | Regulatory Strategy | Biologicals Neha’s Profile linkedin.com/in/neha-parashar Email nehaparashar.niper@gmail.com Welcome to the PharmaCamp with Neha. With this video channel. I would like to <a href='https://www.allfordrugs.com/2022/02/18/what-is-investigational-new-drug-ind-application-neha-parashar/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><a href="http://www.allfordrugs.com/wp-content/uploads/2022/02/str1.jpg" rel="attachment wp-att-11471"><img class="alignnone size-full wp-image-11471" src="http://www.allfordrugs.com/wp-content/uploads/2022/02/str1.jpg" alt="str1" width="200" height="200" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-150x150.jpg 150w, http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-96x96.jpg 96w, http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-24x24.jpg 24w, http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-36x36.jpg 36w, http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-48x48.jpg 48w, http://www.allfordrugs.com/wp-content/uploads/2022/02/str1-64x64.jpg 64w, http://www.allfordrugs.com/wp-content/uploads/2022/02/str1.jpg 200w" sizes="(max-width: 200px) 100vw, 200px" /></a></p><h1 class="title style-scope ytd-video-primary-info-renderer">What is Investigational New Drug (IND) Application? | Regulatory Learnings | Drug Regulatory Affairs</h1><p>https://www.youtube.com/watch?v=NTOtI7HfE9I</p><p> </p><p><iframe title="YouTube video player" src="https://www.youtube.com/embed/NTOtI7HfE9I" width="560" height="315" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p><p> </p><p> </p><p>GUEST AUTHOR</p><div><h1 class="text-heading-xlarge inline t-24 v-align-middle break-words">Neha Parashar, PMP®</h1></div><div class="text-body-medium break-words">Senior Manager Regulatory CMC | Regulatory Project Management | Regulatory Strategy | Biologicals</div><div class="text-body-medium break-words"><section class="pv-contact-info__contact-type ci-vanity-url"><h3 class="pv-contact-info__header t-16 t-black t-bold">Neha’s Profile</h3><div class="pv-contact-info__ci-container t-14"><a class="pv-contact-info__contact-link link-without-visited-state t-14" href="https://www.linkedin.com/in/neha-parashar">linkedin.com/in/neha-parashar</a></div></section><section class="pv-contact-info__contact-type ci-email"><h3 class="pv-contact-info__header t-16 t-black t-bold">Email</h3><div class="pv-contact-info__ci-container t-14"><a class="pv-contact-info__contact-link link-without-visited-state t-14" href="mailto:nehaparashar.niper@gmail.com" target="_blank" rel="noopener noreferrer">nehaparashar.niper@gmail.com</a></div><div class="pv-contact-info__ci-container t-14"><span class="style-scope yt-formatted-string" dir="auto">Welcome to the PharmaCamp with Neha. With this video channel. I would like to spread knowledge about the pharmaceutical world. This is a small initiative from my side to share knowledge with the world, as I feel education is the best gift one can receive or give back to society. Are you a working professional who wants to upgrade your skills? OR a student who wants to make a career in pharmaceuticals? OR are you a person who is interested to learn about the regulatory systems? Then this YouTube channel is for you. In this video, we will about US FDA Investigational New Drug (IND) Application. In my upcoming video, I will provide the stepwise approach for these IND applications. Therefore, this video will serve as the basis for those upcoming videos to explain the concept of INDs. </span></div><div class="pv-contact-info__ci-container t-14"></div><div class="pv-contact-info__ci-container t-14"><span class="style-scope yt-formatted-string" dir="auto">Welcome to PharmaCamp </span><a class="yt-simple-endpoint style-scope yt-formatted-string" dir="auto" spellcheck="false" href="https://www.youtube.com/watch?v=Rpvbzrsuu64&t=0s">https://youtu.be/Rpvbzrsuu64</a></div><div class="pv-contact-info__ci-container t-14"></div><div class="pv-contact-info__ci-container t-14"><span class="style-scope yt-formatted-string" dir="auto">What is Clinical Trial? </span><a class="yt-simple-endpoint style-scope yt-formatted-string" dir="auto" spellcheck="false" href="https://www.youtube.com/watch?v=uAUXEsAC23o&t=0s">https://youtu.be/uAUXEsAC23o</a></div><div class="pv-contact-info__ci-container t-14"></div><div class="pv-contact-info__ci-container t-14"><span class="style-scope yt-formatted-string" dir="auto">About me: I am Neha Parashar, working as a Senior Manager in a pharmaceutical company and based in Germany. I am a passionate healthcare professional, an educator, and a mentor. LinkedIn: </span><a class="yt-simple-endpoint style-scope yt-formatted-string" dir="auto" spellcheck="false" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa19FTVVIQW45WnF1QjZ6T01iUXpIZWxYV1FvZ3xBQ3Jtc0tsb2NKSURoX0hLX0FTb2I5Vnc3cUhuSWIxelpwd293eDlzQzJOZGhQa0VHUWdjS2gxanp0OTlOcUVSd1pFRWlrSzFMSFJJSTNsVnVSeEJEUUhZUUtxcUEtS2pKYnlySkZpMWhJR1U2VDVqTHA1WW83VQ&q=http%3A%2F%2Flinkedin.com%2Fin%2Fneha-parashar" target="_blank" rel="nofollow">http://linkedin.com/in/neha-parashar</a></div></section></div><p>/////////</p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2022%2F02%2F18%2Fwhat-is-investigational-new-drug-ind-application-neha-parashar%2F&title=What%20is%20investigational%20new%20drug%20%28IND%29%20Application%3F%20%20Neha%20parashar" id="wpa2a_16"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>Anthony crasto is now Consultant Glenmark Lifesciences at Glenmark Life Sciences!</title> <link>https://www.allfordrugs.com/2022/01/18/anthony-crasto-is-now-consultant-glenmark-lifesciences-at-glenmark-life-sciences/</link> <pubDate>Tue, 18 Jan 2022 06:28:41 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[ANTHONY CRASTO]]></category> <category><![CDATA[companies]]></category> <category><![CDATA[anthony crasto]]></category> <category><![CDATA[CONSULTANT]]></category> <category><![CDATA[glenmark]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11467</guid> <description><![CDATA[I’m happy to share that I’m starting a new position as Consultant Glenmark Lifesciences at Glenmark Life Sciences! 17th Jan 2022, A new innings I retired 16th Jan 2022 at 58 yrs from Glenmark . completed 16 yrs 2 months 30 plus years in the field of Process research   AS ON DEC2021 3,491,869 VIEWS ON <a href='https://www.allfordrugs.com/2022/01/18/anthony-crasto-is-now-consultant-glenmark-lifesciences-at-glenmark-life-sciences/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><a href="http://www.allfordrugs.com/wp-content/uploads/2022/01/ls.jpg" rel="attachment wp-att-11468"><img class="alignnone size-full wp-image-11468" src="http://www.allfordrugs.com/wp-content/uploads/2022/01/ls.jpg" alt="ls" width="543" height="389" srcset="http://www.allfordrugs.com/wp-content/uploads/2022/01/ls-300x215.jpg 300w, http://www.allfordrugs.com/wp-content/uploads/2022/01/ls.jpg 543w" sizes="(max-width: 543px) 100vw, 543px" /></a></p><p>I’m happy to share that I’m starting a new position as Consultant Glenmark Lifesciences at <a href="https://www.linkedin.com/company/glenmark-life-sciences/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base_recent_activity_details_all%3BZ0qI6BxYROObewEBX74zSQ%3D%3D" data-attribute-index="0" data-entity-hovercard-id="urn:li:fs_miniCompany:64766169" data-entity-type="MINI_COMPANY" data-ntt-old-href="https://www.linkedin.com/company/glenmark-life-sciences/">Glenmark Life Sciences</a>!<br />17th Jan 2022, A new innings</p><p>I retired 16th Jan 2022 at 58 yrs from Glenmark . completed 16 yrs 2 months</p><p>30 plus years in the field of Process research</p><p> </p><figure class="wp-block-image"><img src="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2021/12/str1-17-300x160.jpg" srcset="https://i0.wp.com/drugapprovalsint.com/wp-content/uploads/2021/12/str1-17-300x160.jpg?zoom=2 1.5x" alt="str1" width="300" height="156" /></figure><figure class="wp-block-image"><img src="http://s08.flagcounter.com/count/lQv5/bg_FFFFFF/txt_000000/border_CCCCCC/columns_2/maxflags_20/viewers_0/labels_1/pageviews_1/flags_1/" alt="Flag Counter" /></figure><h3 id="as-on-dec2021-3-491-869-views-on-blog-worldreach-availablefor-your-advertisement"><strong>AS ON DEC2021 3,491,869 VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT</strong></h3><figure id="block-97f20ca3-89bf-4f06-8d2e-7bfa14bb5a13" class="wp-block-image"><img src="https://newdrugapprovals.files.wordpress.com/2021/09/wdt-16.jpg" alt="wdt-16" /></figure><p id="block-3ef869a1-6245-4000-8a22-7653283fbf20">join me on Linkedin</p><h3 id="block-bda9074d-6d6c-4814-8b17-1f6523150f48"><a href="https://www.google.co.in/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&sqi=2&ved=0CDAQFjAA&url=http%3A%2F%2Fin.linkedin.com%2Fin%2Famcrasto&ei=HC79UIPrOImQrgfThIHgCA&usg=AFQjCNG33yHjtsBnClvr_2VJAspNSOCHjA&sig2=S2Nt_xtNQcl_MGwq9T_I-Q&bvm=bv.41248874,d.bmk"><em>Anthony Melvin Crasto</em> Ph.D – India | <em>LinkedIn</em></a></h3><p id="block-90534d59-b193-4609-8d90-1565a8bd4022">join me on Researchgate</p><h3 id="block-2e2f1d69-cf4c-4628-ad8b-f07892af22ec"><a href="https://www.researchgate.net/profile/Anthony_Crasto">RESEARCHGATE</a></h3><figure id="block-a1fe75ef-39d0-4b9f-a8db-f2ebbfd11320" class="wp-block-image"><img src="https://newdrugapprovals.files.wordpress.com/2018/03/research.jpg?w=27" srcset="https://newdrugapprovals.files.wordpress.com/2018/03/research.jpg?w=27&zoom=2 1.5x" alt="This image has an empty alt attribute; its file name is research.jpg" width="35" height="6" /></figure><p id="block-b8c6f3e7-356c-42fc-b071-f74093cc5916">join me on Facebook</p><h3 id="anthony-melvin-crasto-dr-facebook"><em>Anthony Melvin Crasto</em> Dr. | <em>Facebook</em></h3><ul id="block-cc73c381-0233-4cde-8597-91f3069d5326"><li><a href="https://twitter.com/amcrasto">Twitter</a></li><li><a href="http://www.facebook.com/anthonymelvin.crasto">FACEBOOK</a></li></ul><p id="block-148b08ef-8104-4070-b679-420a0c60f41e">join me on twitter</p><p><em>Anthony Melvin Crasto</em> Dr. | <em>twitter</em></p><p id="block-8632ae1d-e603-4b92-9b3b-e3ec8b2dd9c7">+919321316780 call whatsaapp</p><p>EMAIL. amcrasto@amcrasto</p><p>/////////////////////////////////////////////////////////////////////////////</p><p>ANTHONY CRASTO, GLENMARK, CONSULTANT</p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2022%2F01%2F18%2Fanthony-crasto-is-now-consultant-glenmark-lifesciences-at-glenmark-life-sciences%2F&title=Anthony%20crasto%20is%20now%20Consultant%20Glenmark%20Lifesciences%20at%C2%A0Glenmark%20Life%20Sciences%21" id="wpa2a_18"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> <item> <title>ASMF</title> <link>https://www.allfordrugs.com/2021/09/15/asmf/</link> <pubDate>Wed, 15 Sep 2021 10:01:32 +0000</pubDate> <dc:creator><![CDATA[DR ANTHONY MELVIN CRASTO Ph.D]]></dc:creator> <category><![CDATA[Uncategorized]]></category> <guid isPermaLink="false">http://www.allfordrugs.com/?p=11324</guid> <description><![CDATA[What is an ASMF? An Active Substance Master File (ASMF), or formerly known as European Drug Master File (EDMF) procedure, is a set of documents that protects the valuable confidential intellectual property of the manufacturer. The main objective of the Active Substance Master File (ASMF) procedure, formerly known as the European Drug Master File (EDMF) procedure, is to allow <a href='https://www.allfordrugs.com/2021/09/15/asmf/' class='excerpt-more'>[...]</a>]]></description> <content:encoded><![CDATA[<p><img src="https://slideplayer.com/slide/12432269/74/images/15/EU+DMF+%28EDMF+or+ASMF%29.jpg" alt="What is a Drug Master File? - ppt download" /></p><div class="wWOJcd" tabindex="0"><div id="exacc_S8FBYeKaEKTF4-EP67q16AE39" class="iDjcJe IX9Lgd wwB5gf">What is an ASMF?</div><div class="YsGUOb"></div><div class="r21Kzd" data-hveid="CCoQAQ" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Quk56BAgqEAE"></div></div><div id="exacc_S8FBYeKaEKTF4-EP67q16AE41" class="MBtdbb" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Q7NUEegQIKhAD"><div class="ymu2Hb"><div id="_S8FBYeKaEKTF4-EP67q16AE44" class="t0bRye a2qtDc r2fjmd" data-hveid="CCoQBA" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Qu04oAHoECCoQBA"><div id="S8FBYeKaEKTF4-EP67q16AE__30"><div class="wDYxhc" data-md="61"><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CB8QAA"><span class="ILfuVd NA6bn"><span class="hgKElc">An <b>Active Substance Master File</b> (ASMF), or formerly known as European Drug Master File (EDMF) procedure, is a set of documents that protects the valuable confidential intellectual property of the manufacturer.</span></span></div></div></div></div></div></div><p>The main objective of the <a id="glossary-term-43124" class="ecl-link glossary-term" title="Documentation providing detailed information on the manufacturing of the active substance of a medicine. More information can be found on the eSubmissions website under 'Electronic Active Substance Master Files (eASMF)'." href="https://www.ema.europa.eu/en/glossary/active-substance-master-file" target="_blank">Active Substance Master File</a> (ASMF) procedure, formerly known as the European Drug Master File (EDMF) procedure, is to allow valuable confidential intellectual property or ‘know-how’ of the manufacturer of the <a id="glossary-term-43123" class="ecl-link glossary-term" title="The substance responsible for the activity of a medicine." href="https://www.ema.europa.eu/en/glossary/active-substance" target="_blank">active substance</a> (ASM) to be protected, while at the same time allowing the Applicant or <a id="glossary-term-43236" class="ecl-link glossary-term" title="The approval to market a medicine in one, several or all European Union Member States." href="https://www.ema.europa.eu/en/glossary/marketing-authorisation" target="_blank">Marketing Authorisation</a> (MA) holder to take full responsibility for the <a id="glossary-term-43242" class="ecl-link glossary-term" title="A substance or combination of substances that is intended to treat, prevent or diagnose a disease, or to restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action." href="https://www.ema.europa.eu/en/glossary/medicinal-product" target="_blank">medicinal product</a> and the quality and quality control of the <a id="glossary-term-43123" class="ecl-link glossary-term" title="The substance responsible for the activity of a medicine." href="https://www.ema.europa.eu/en/glossary/active-substance" target="_blank">active substance</a>. <a id="glossary-term-43250" class="ecl-link glossary-term" title="A medicines regulatory authority in a European Union Member State." href="https://www.ema.europa.eu/en/glossary/national-competent-authority" target="_blank">National Competent Authorities</a>/EMA thus have access to the complete information that is necessary for an evaluation of the suitability of the use of the <a id="glossary-term-43123" class="ecl-link glossary-term" title="The substance responsible for the activity of a medicine." href="https://www.ema.europa.eu/en/glossary/active-substance" target="_blank">active substance</a> in the <a id="glossary-term-43242" class="ecl-link glossary-term" title="A substance or combination of substances that is intended to treat, prevent or diagnose a disease, or to restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action." href="https://www.ema.europa.eu/en/glossary/medicinal-product" target="_blank">medicinal product</a>.</p><div class="ecl-list-item__body"><h3 class="ecl-list-item__title ecl-heading">Final Guideline on Active Substance Master File Procedure – Revision 4 <small class="ema-u-color-grey-2">(PDF/358.28 KB)</small></h3><div class="ema-u-color-grey-2"><small>Adopted</p><p>First published: 14/12/2018<br />Legal effective date: 17/06/2019<br />CHMP/QWP/227/02 Rev 4, EMEA/CVMP/134/02 Rev 4 Corr.</small></div><div class="ema-u-color-grey-2"><a href="https://www.ema.europa.eu/en/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf">https://www.ema.europa.eu/en/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf</a></div></div><p> </p><p> </p><div class="wWOJcd" tabindex="0"><div id="exacc_S8FBYeKaEKTF4-EP67q16AE38" class="iDjcJe IX9Lgd wwB5gf">What is CEP and ASMF?</div><div class="YsGUOb"></div><div class="r21Kzd" data-hveid="CCkQAQ" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Quk56BAgpEAE"></div></div><div id="exacc_S8FBYeKaEKTF4-EP67q16AE40" class="MBtdbb" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Q7NUEegQIKRAD"><div class="ymu2Hb"><div id="_S8FBYeKaEKTF4-EP67q16AE46" class="t0bRye a2qtDc r2fjmd" data-hveid="CCkQBA" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Qu04oAHoECCkQBA"><div id="S8FBYeKaEKTF4-EP67q16AE__33"><div class="wDYxhc" data-md="61"><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CCAQAA"><span class="ILfuVd NA6bn"><span class="hgKElc">The ASMF holder may have an ASMF as well as a <b>Certificate of Suitability (CEP)</b> issued by EDQM for a single active substance. Generally, it is however not acceptable that the Applicant/MA holder refers to an ASMF as well as to a CEP for a single active substance of a particular MAA/MAV.</span></span></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CCAQAA"></div></div></div></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CCAQAA"><div class="wWOJcd" tabindex="0"><div id="exacc_S8FBYeKaEKTF4-EP67q16AE57" class="iDjcJe IX9Lgd wwB5gf">What is an ASMF in pharmaceutical industry?</div><div class="YsGUOb"></div><div class="r21Kzd" data-hveid="CDUQAQ" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Quk56BAg1EAE"></div></div><div id="exacc_S8FBYeKaEKTF4-EP67q16AE58" class="MBtdbb" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Q7NUEegQINRAD"><div class="ymu2Hb"><div id="_S8FBYeKaEKTF4-EP67q16AE60" class="t0bRye a2qtDc r2fjmd" data-hveid="CDUQBA" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Qu04oAHoECDUQBA"><div id="S8FBYeKaEKTF4-EP67q16AE__36"><div class="wDYxhc" data-md="61"><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CDYQAA"><span class="ILfuVd NA6bn"><span class="hgKElc">The main objective of the <b>Active Substance Master File</b> (ASMF) procedure, formerly known as the European Drug Master File (EDMF) procedure, is to allow valuable confidential intellectual property or ‘know-how’ of the manufacturer of the active substance (ASM) to be protected, while at the same time allowing the …</span></span></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CDYQAA"></div></div></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CDYQAA"><div class="wWOJcd" tabindex="0"><div id="exacc_S8FBYeKaEKTF4-EP67q16AE36" class="iDjcJe IX9Lgd wwB5gf">What is the difference between Asmf and DMF?</div><div class="YsGUOb"></div><div class="r21Kzd" data-hveid="CCgQAQ" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Quk56BAgoEAE"></div></div><div id="exacc_S8FBYeKaEKTF4-EP67q16AE37" class="MBtdbb" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Q7NUEegQIKBAD"><div class="ymu2Hb"><div id="_S8FBYeKaEKTF4-EP67q16AE42" class="t0bRye a2qtDc r2fjmd" data-hveid="CCgQBA" data-ved="2ahUKEwii7Lq92YDzAhWk4jgGHWtdDR0Qu04oAHoECCgQBA"><div id="S8FBYeKaEKTF4-EP67q16AE__39"><div class="wDYxhc" data-md="61"><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CB4QAA"><span class="ILfuVd NA6bn"><span class="hgKElc">An Active Substance Master File (ASMF) is the currently recognised term in Europe, formerly known as European Drug Master File (EDMF) or a US-Drug Master file (US-DMF) in the United States.</span></span></div></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CB4QAA"><div class="wWOJcd" tabindex="0"><div id="exacc__8JBYba4FtPG4-EP8YOKgAY9" class="iDjcJe IX9Lgd wwB5gf">What is a EDQM CEP certificate?</div><div class="YsGUOb"></div><div class="r21Kzd" data-hveid="CAgQAQ" data-ved="2ahUKEwj2s7SN24DzAhVT4zgGHfGBAmAQuk56BAgIEAE"></div></div><div id="exacc__8JBYba4FtPG4-EP8YOKgAY10" class="MBtdbb" data-ved="2ahUKEwj2s7SN24DzAhVT4zgGHfGBAmAQ7NUEegQICBAD"><div class="ymu2Hb"><div class="t0bRye a2qtDc r2fjmd" data-hveid="CAgQBA" data-ved="2ahUKEwj2s7SN24DzAhVT4zgGHfGBAmAQu04oAHoECAgQBA"><div id="_8JBYba4FtPG4-EP8YOKgAY__12"><div class="wDYxhc" data-md="61"><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CAQQAA"><span class="ILfuVd NA6bn"><span class="hgKElc">To obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP), applicants must send in electronic format the following documentation to the Certification of Substances Department (DCEP) of the EDQM: a <b>completed</b> application form which includes your invoicing details.</span></span></div></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CAQQAA"></div></div></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CAQQAA"><table border="0" width="100%"><tbody><tr><td align="left"><p class="T18B">Electronic Active Substance Master Files (eASMF)</p></td></tr></tbody></table></div><div class="t0bRye a2qtDc r2fjmd" data-hveid="CAgQBA" data-ved="2ahUKEwj2s7SN24DzAhVT4zgGHfGBAmAQu04oAHoECAgQBA"><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CAQQAA"><p class="T10">ASMF Holders who are supplying substances to more than one Centrally Authorised Product (CAP) should submit their ASMF to the Agency once and not for each application.</p><p class="T10">The use of <a href="http://esubmission.ema.europa.eu/ectd/index.html">eCTD</a> is mandatory for all for centralised procedure human ASMF submissions since 1 July 2016. The use of eCTD is mandatory for ASMFs used for DCP/MRP human procedures from 1 January 2018. Use of eCTD is mandatory for new national MAAs since 1 July 2018 and from 1 January 2019 for all other submission types. The relevant guidance should be followed and the technical <a href="http://esubmission.ema.europa.eu/ectd/index.html">eCTD validation criteria</a> must be passed.</p><p class="T10">To ensure that the above is followed promptly, please refer to the human <a href="https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pre-authorisation-guidance" target="_blank">EMA Pre-authorisation guidance</a> carefully and apply for an EMEA/ASMF/XXXXX number at your earliest convenience by submitting the <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/08/WC500147835.doc" target="_blank">EMEA/ASMF request form</a>.</p><p class="T10">For veterinary medicines the accepted electronic format is <a href="http://esubmission.ema.europa.eu/tiges/vetesub.htm" target="_blank">VNeeS</a> and NeeS and for ASMFs also exceptionally eCTD is allowed. More information can be found from the <a href="https://www.ema.europa.eu/en/veterinary-regulatory/marketing-authorisation/veterinary-pre-submission-qa-introduction">Veterinary Pre-submission guidance</a>.</p><p>Please take a note of the voluntary <a href="http://www.hma.eu/306.html" target="_blank">EU ASMF Assessment worksharing</a>. A different <a href="http://www.hma.eu/306.html" target="_blank">EU/ASMF request form</a> should be submitted when requesting participation in the EU worksharing procedure.</p><p class="T10"><strong>It is very important to note that the above two initiatives are different.</strong></p><ul><li class="T10">The EMA eASMF submission rules are mandatory since 1st September 2013 and are applicable to all Centralised applications.</li><li class="T10">The EU Assessment worksharing initiative is valid for Centralised and Decentralised procedures.</li></ul><p class="T10">A valid ASMF should have <u>either</u> an EMEA/ASMF number or an EU/ASMF number, depending on the intended use of the ASMF by its holder. When applying for EMEA or EU ASMF numbers, or submitting any documentation quoting these, please note that they are not inter-changeable. Only <strong>one </strong>ASMF number should be quoted.</p><p>It is mandatory to use XML delivery files for ASMF submissions using the eSubmission Gateway and the Web Client.</p></div></div></div><div class="LGOjhe" data-attrid="wa:/description" data-hveid="CAQQAA"><p class="T12maroon">Related Documents</p><p class="T10"><a href="http://esubmission.ema.europa.eu/eASMF/archived_documents.htm">Archived documents</a></p><ul class="T10"><li class="T10"><a href="http://esubmission.ema.europa.eu/eASMF/ASMF%20eCTD%20Guideline%20.pdf">EU Harmonised Technical Guidance for ASMF Submissions in eCTD format version 2.3</a><strong>(01.07.2020)<span class="T10Bindred">Updated</span></strong></li><li class="T10"><a class="T10" href="https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pre-authorisation-guidance" target="_blank">EMA Pre-authorisation guidance</a></li><li class="T10">EMEA/ASMF number request template <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/08/WC500147835.doc" target="_blank">request form</a></li><li class="T10">EU/ASMF number request template <a href="http://www.hma.eu/306.html" target="_blank">request form</a></li><li class="T10">Letter of Access <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2012/07/WC500129998.doc" target="_blank">Template</a> (Previously Annex 2), Template Administrative Information – (Previously Annex 3), Template Withdrawal of Access Letter –Should be filled in in accordance of the ASMF type (EU/ASMF/XXXXX or EMEA/ASMF/XXXXX)</li><li class="T10"><a href="http://www.hma.eu/306.html" target="_blank">EU ASMF Assessment Worksharing</a></li><li class="T10"><a href="http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500129994" target="_blank">Active Substance Master File Procedure Guidance – Human</a></li><li class="T10"><a href="https://www.ema.europa.eu/en/veterinary-regulatory/marketing-authorisation/pre-submission-guidance-qa-introduction/qa-21-40" target="_blank">Active Substance Master File Guidance – Veterinary</a></li><li class="T10"><span class="T10"><a href="http://esubmission.ema.europa.eu/eASMF/asmf-eurotriptan-maleate.zip">Example of ASMF in eCTD format</a></span></li></ul><div id="c6103" class="csc-frame csc-frame-default"><h1 class="csc-firstHeader">ACTIVE SUBSTANCE MASTER FILE (ASMF)</h1></div><div id="c6105" class="csc-frame csc-frame-default"><p><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129994.pdf" target="_blank"><acronym title="European Medicines Agency">EMA</acronym> Guideline on Active Substance Master File Procedure</a></p></div><div id="c6106" class="csc-frame csc-frame-default"><p><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133204.pdf" target="_blank"><acronym title="European Medicines Agency">EMA</acronym> Additional guidance on documents relating to an Active Substance Master File</a></p></div><div id="c6107" class="csc-frame csc-frame-default"><p><a href="http://www.hma.eu/334.html" target="_blank">Templates for Active Substance Master File (ASMF) procedures</a></p></div><div id="c6108" class="csc-frame csc-frame-default"><p><a href="http://www.hma.eu/20.html" target="_blank">CMDh-CMDv Questions & Answers – Active Substance Master File (ASMF)</a></p></div><div id="c6109" class="csc-frame csc-frame-default"><p><a href="http://www.hma.eu/306.html" target="_blank">CMDh website for latest advice on ASMF procedures (Joint WG website including procedural guidance)</a></p></div><div id="c6419" class="csc-frame csc-frame-default"><p><a href="http://www.hma.eu/306.html" target="_blank">Training presentations on Active Substance Master File (ASMF) work sharing procedure</a>:</p><p> </p><ul><li>ASMF worksharing – Introduction to the procedure (October 2018)</li><li>Requesting an <acronym title="European Union">EU</acronym>_ASMF repository number (October 2018)</li><li>Submitting an initial worksharing ASMF (October 2018)</li><li>Determining the parent procedure (October 2018)</li><li>Assessment report template (October 2018)</li><li>Sharing assessment reports (October 2018)</li><li>Submitting a variation to an ASMF (October 2018)</li><li>Use of an approved ASMF in a new procedure (October 2018)</li></ul></div></div><p>An Active Substance Master File (ASMF), or formerly known as European Drug Master File (EDMF) procedure, is a set of documents that protects the valuable confidential intellectual property of the manufacturer. The purpose of an ASMF is to provide the Health Authorities (HAs) with complete information of the active substance used in a drug product to evaluate its suitability for the product. It also allows the Marketing Authorization Holder (MAH) of the product to take the responsibility for the quality of the active substance used in the product.</p><h2>ASMF Content</h2><p>An ASMF must contain all the scientific information related to the active substance. The information of an ASMF is divided into two parts:</p><ol><li>Applicant Part (AP) – Contains information considered as non-confidential by the MAH</li><li>Restricted Part – Contains confidential information</li></ol><h2>ASMF Usage</h2><p>An ASMF is submitted only to support a Marketing Authorisation Application (MAA) or Marketing Authorisation Variation (MAV). It is used for the following active substances:</p><ol><li>Active substances that are new</li><li>Already existing active substances, which are excluded from the European Pharmacopoeia (Ph. Eur.)</li><li>Pharmacopoeial active substances, which are included in the (Ph. Eur.)</li></ol><p>An ASMF holder is required to submit the following to the MAH holder:</p><ul><li>A copy of AP’s latest version</li><li>A copy of the summary/detailed version of AP’s latest version</li><li>A copy of the letter of access, which has not been previously submitted for the same product</li></ul><p>A single active substance can have both, an ASMF as well as a Certificate of Suitability (CEP). However, the MAH cannot refer to both the documents for a single active substance. In case, the information present in a CEP is insufficient, only then both the documents can be referred.</p></div></div></div></div></div></div></div></div></div></div></div></div></div><p>////////////////// <a id="glossary-term-43124" class="ecl-link glossary-term" title="Documentation providing detailed information on the manufacturing of the active substance of a medicine. More information can be found on the eSubmissions website under 'Electronic Active Substance Master Files (eASMF)'." href="https://www.ema.europa.eu/en/glossary/active-substance-master-file" target="_blank">Active substance master file</a>, ASMF, letter of access, submission letter</p><p><a class="a2a_dd a2a_target addtoany_share_save" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.allfordrugs.com%2F2021%2F09%2F15%2Fasmf%2F&title=ASMF" id="wpa2a_20"><img src="https://www.allfordrugs.com/wp-content/plugins/add-to-any/share_save_256_24.png" width="256" height="24" alt="Share"/></a></p>]]></content:encoded> </item> </channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
